Health Insurance Stocks Rally Amid Market Optimism
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 23 2025
0mins
Should l Buy HUM?
Source: Coinmarketcap
Humana Inc's stock rose by 3.00% during regular trading, reaching a 20-day high. This increase comes as health insurance stocks, including Humana, Centene, and Elevance Health, all experienced gains of over 3% on Monday, reflecting resilience in the sector amid a challenging economic environment. The broader market, however, faced pressure with the Nasdaq-100 down 1.36% and the S&P 500 down 0.70%, indicating a sector rotation where health insurance stocks outperformed despite overall market weakness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to rise
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 236.440
Low
231.00
Averages
290.39
High
344.00
Current: 236.440
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Financial Performance Overview: Humana's Q1 2026 results align with expectations, although specific revenue and EPS figures were not disclosed, management noted that the medical cost trend continues to outpace program funding, indicating future profitability pressures.
- Acquisition and Membership Growth: The company completed the acquisition of MaxHealth, resulting in an increase of approximately 50,000 Medicaid members, primarily driven by program starts in Michigan, Illinois, and South Carolina, enhancing its competitive position in the market.
- Leadership Transition: Insurance segment President George Renaudin will retire effective June 29, 2026, with Aaron Martin taking over day-to-day management, ensuring a smooth leadership transition to support the company's long-term strategy.
- Future Outlook: Management expects to achieve a sustainable margin of at least 3% by 2028, despite the widening gap between medical costs and funding, planning to adjust benefits to maintain this target.
See More
- Trend of Benefit Cuts: Medicare Advantage plans are expected to reduce extra benefits like gym memberships and vision and dental coverage next year, potentially affecting the choices of 70 million enrollees, leading to customer attrition and a decline in market share.
- Impact of Payment Adjustments: The U.S. government announced a 2.48% average increase in payments for Medicare Advantage plans for 2027, but insurance executives believe this increase is insufficient to cover costs, prompting companies like Humana to cut benefits to meet profit targets.
- Intensifying Market Competition: Humana's COO indicated that all insurers are likely to cut back on benefits, with Humana expected to make the most significant reductions, which could affect its competitiveness in the market, especially ahead of the upcoming midterm elections where voter anger over rising costs may influence political dynamics.
- Customer Reactions and Political Pressure: Analysts suggest that customers may be surprised by the increase in out-of-pocket expenses, potentially leading to heightened political pressure that could impact the future direction of Medicare policies, particularly among senior voters whose voting behavior may be influenced.
See More
- Seagate Strong Performance: Seagate Technology forecasts fourth-quarter revenue of $3.45 billion and adjusted earnings of $5 per share, exceeding market expectations and driving its stock price up nearly 18%, indicating robust performance and growth potential in the data storage market.
- Memory Stocks Rally: Following Seagate's earnings boost, Western Digital shares surged over 10%, Sandisk jumped 7.5%, and Micron rose over 4%, reflecting increased investor confidence and optimism in the memory storage sector.
- Booking Holdings Lowers Guidance: Despite Booking Holdings beating first-quarter expectations, its stock fell about 4.5% after it downgraded its full-year adjusted EPS growth forecast to the low to mid-teens, raising concerns about the travel industry's outlook.
- NXP Semiconductor Strong Rebound: NXP Semiconductor reported first-quarter adjusted earnings of $3.05 per share and revenue of $3.18 billion, both exceeding analyst expectations, leading to an over 18.5% stock price increase, showcasing its competitiveness and growth potential in the semiconductor market.
See More
- Strong Earnings Report: Humana's Q1 2026 revenue reached $39.65 billion, exceeding market expectations by $260 million, with insurance revenue rising 23% year-over-year to $38.06 billion, indicating robust performance in its insurance segment.
- Earnings Outlook Downgrade: Despite the strong Q1 results, Humana reaffirmed its adjusted earnings per share outlook for 2026 at a minimum of $8.36, below the consensus of $8.71, reflecting anticipated pressures from the 2025 Medicare Star Ratings cut and a projected 15% year-over-year decline.
- Rising Expense Ratio: The company's benefit expense ratio increased to 89.4% from 87% in the prior year, indicating heightened cost pressures that could impact future profitability and investor confidence.
- Healthcare Services Growth: Humana's healthcare services arm, CenterWell, generated $6.1 billion in revenue for Q1, a year-over-year increase of approximately 20%, surpassing the consensus estimate of $5.8 billion, demonstrating ongoing growth potential in the healthcare services sector.
See More
- Earnings Performance: Humana reported Q1 2026 earnings per share (EPS) of $9.83 and adjusted EPS of $10.31, both at the high end of the company's guidance, indicating strong profitability and market confidence.
- Insurance Benefit Ratio: The insurance segment's GAAP benefit ratio was 89.4%, slightly better than management's guidance, affirming a 2026 benefit ratio target of 92.75%, reflecting effective cost control and operational efficiency.
- Medicare Membership Growth: The company affirmed a projected 25% growth in individual Medicare Advantage membership for 2026, driven by new sales and improved customer service strategies, showcasing success in market expansion and customer retention.
- Strategic Leadership Transition: Humana announced that Insurance Segment President George Renaudin will retire on June 29, 2026, with Aaron Martin taking over, ensuring a smooth leadership transition that supports the company's strategic execution and market competitiveness.
See More









